Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall

Executive Summary

Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.

You may also be interested in...



Rise And Fall: PDUFA Fees Go Up But Some GDUFA Levies Come Down In FY 2015

NDA/BLAs with clinical data will cost 7.7% more starting Oct. 1, bringing the application fee to $2.34 million.

GDUFA’s Perfect Storm: Approvals Drop, Submissions Jump

FDA increases “complete response” and refuse-to-receive actions in the first half of FY 2014 compared to the previous year, efforts the agency says will move pending applications closer to approval.

GDUFA: Fee Avoidance Affects Rates Again

Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS055523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel